<DOC>
	<DOCNO>NCT01363778</DOCNO>
	<brief_summary>This study design evaluate effect ketoconazole Pharmacokinetic profile tivozanib .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate The Effect Ketoconazole Pharmacokinetics Tivozanib Healthy Subjects</brief_title>
	<detailed_description>This Phase 1 , open-label , two-period , single-sequence study design evaluate effect steady-state ketoconazole PK profile , safety , tolerability single 1.5-mg tivozanib dose . On Day 1 first period , subject receive single 1.5-mg dose tivozanib remain unit least 48 hour postdose followed outpatient visit PK sample safety assessment 3 week postdose . For Period 2 , subject administer 400 mg ketoconazole daily ( QD ) 3 day . On 4th day Period 2 , 1.5mg tivozanib administer 400mg ketoconazole . PK sample continue 3-weeks postdose subject continue receive 400mg ketoconazole daily . An end study visit complete 1-week last dose ketoconazole .</detailed_description>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>1 . Males female , 18 55 year age , inclusive . 2 . Body mass index ( BMI ) within range 18.5 31.0 kg/m2 , inclusive . 3 . In good health , determine clinically significant finding medical history , physical examination , 12lead ECG , vital sign . 4 . Clinical laboratory evaluation ( include chemistry panel comprise 20 analytes [ Chem20 , include liver function test ; fast approximately 10 hour ] , complete blood count [ CBC ] , urinalysis ) exceed 2 x upper limit normal ( ULN ) &lt; low limit normal ( LLN ) , unless deem clinically significant Investigator . 5 . Nonsmokers ( refrain tobacco usage , include smokeless tobacco , nicotine patch , etc. , 6 month prior Screening ) , verified cotinine test Screening study period Checkin . 6 . Negative test select drug abuse Screening ( include alcohol ) study period Checkin ( include alcohol ; Appendix A ) . 7 . Negative hepatitis panel ( include hepatitis B virus surface antigen [ HBsAg ] hepatitis C virus antibody [ antiHCV ] negative human immunodeficiency virus [ HIV ] antibody screen ; Appendix A ) . 8 . Females pregnant , nonlactating , either postmenopausal least 1 year , surgically sterile ( eg , tubal ligation , hysterectomy ) least 90 day prior Screening , agree use least 1 follow form contraception inform consent 45 day Study Completion : nonhormonal intrauterine device spermicide ; female condom spermicide ; contraceptive sponge spermicide ; diaphragm spermicide ; cervical cap spermicide ; male sexual partner agree use male condom spermicide ; sterile sexual partner . For female , serum pregnancy test result must negative Screening study period Checkin . 9 . Male subject either sterile agree use , period inform consent 45 day follow Study Completion , 1 follow approve method contraception : double barrier method ( eg , male condom spermicide , use female sexual partner intrauterine device spermicide , female condom spermicide , contraceptive sponge spermicide , diaphragm spermicide , use cervical cap spermicide ) ; sterile sexual partner ; female sexual partner use intravaginal system ( eg , NuvaRing® ) ; partner use oral , implantable , transdermal , injectable contraceptive . 10 . Able comprehend willing sign Informed Consent Form ( ICF ) . 1 . Significant history clinical manifestation significant metabolic/endocrine , allergic , dermatological , hepatic , renal , hematological , pulmonary , immune , cardiovascular , gastrointestinal , genitourinary , neurological , psychiatric disorder ( determined Investigator Sponsor 's Medical Monitor ) . 2 . History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator . 3 . History stomach intestinal surgery , nephrectomy , cholecystectomy , resection would potentially alter absorption and/or excretion orally administer drug determine Investigator ( appendectomy and/or hernia repair may allow ) . 4 . Diagnosis alcoholism drug addiction within 1 year prior Period 1 Checkin . 5 . Participation investigational drug study receipt investigational study drug occur within 5 halflives 30 day , whichever longer , prior Period 1 Checkin . 6 . Use prescription medication product within 14 day prior Period 1 Checkin . 7 . Use overthecounter ( OTC ) , nonprescription , systemic preparation ( include vitamin , mineral , phytotherapeutic , herbal , dietary supplement , plant derive preparation ) within 7 day prior study period Checkin . 8 . Consumption food beverage contain alcohol , grapefruit , Seville orange , caffeine within 72 hour prior study period Checkin . 9 . Use know hepatic renal clearance alter agent ( eg , ketoconazole , erythromycin , cimetidine , barbiturate , phenothiazine , herbal/plant derive preparation St. John 's Wort ) period 60 day prior Period 1 Checkin . 10 . Poor peripheral venous access . 11 . Donation blood ≥ 250 mL 30 day prior Period 1 Checkin Study Completion , inclusive , plasma 2 week prior Period 1 Checkin Study Completion , inclusive . 12 . Receipt blood product within 2 month prior Period 1 Checkin . 13 . Blood pressure great 140/90 mmHg confirm repeat Screening Period 1 Checkin . Up 2 repeat may conduct . 14 . History azole antifungal hypersensitivity . 15 . Any acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>AV-951</keyword>
	<keyword>Tivozanib</keyword>
	<keyword>Healthy Subjects</keyword>
	<keyword>ketoconazole</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>